Erythropoietins, Erythropoietic Factors, and Erythropoiesis

1. Front Matter

   Pages I-XVIII

   PDF

2. Background

   1. Front Matter

      Pages 1-1

      PDF

   2. Erythropoiesis: an overview

      • Bruce E. Torbett, Jeffrey S. Friedman

      Pages 3-18

   3. Regulation of endogenous erythropoietin production

      • David R. Mole, Peter J. Ratcliffe

      Pages 19-40

   4. Biology of erythropoietin

      • Graham Molineux, Angus M. Sinclair

      Pages 41-60

   5. Erythropoiesis—genetic abnormalities

      • Josef T. Prchal, Xylina T. Gregg

      Pages 61-74

3. Erythropoiesis-stimulating agents

   1. Front Matter

      Pages 75-75

      PDF

   2. Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin

      • Mary Ann Foote

      Pages 77-85

   3. Commercial production of recombinant erythropoietins

      • Alice S. Chuck, Adrian Distler, Shane A. Sander, Rohini R. Deshpande, Gregg Nyberg, James E. Seely

      Pages 87-104

   4. Biosimilar epoetins

      • Huub Schellekens

      Pages 105-114

   5. New molecules and formulations

      • Steven G. Elliott

      Pages 115-140

4. Erythropoietin receptor

   1. Front Matter

      Pages 141-141

      PDF

   2. Structural basis for the signal transduction of erythropoietin

      • Timothy D. Osslund

      Pages 143-153

   3. Intracellular signaling by the erythropoietin receptor

      • Harvey F. Lodish, Saghi Ghaffari, Merav Socolovsky, Wei Tong, Jing Zhang

      Pages 155-174

   4. Mechanism of erythropoietin receptor activation

      • Stefan N. Constantinescu

      Pages 175-196

5. Clinical utility

   1. Front Matter

      Pages 197-197

      PDF

   2. Pharmacokinetics of erythropoiesis-stimulating agents

      • Sameer Doshi, Juan Jose Perez-Ruixo, Graham R. Jang, Andrew T. Chow

      Pages 199-223

   3. Use of erythropoietic stimulating agents in the setting of renal disease

      • David A. Goodkin

      Pages 225-248

   4. Abuse of recombinant erythropoietins and blood products by athletes

      • Don H. Catlin, Caroline K. Hatton

      Pages 249-278

   5. Role and regulation of iron metabolism in erythropoiesis and disease

      • Tara L. Arvedson, Barbra J. Sasu

      Pages 279-298

Research on, and interest in, red blood cell formation spans several centuries and was thought to have peaked in the 1980s with the cloning of the eryth- poietin (EPO) gene. In the years subsequent to the cloning of EPO and its expression as a recombinant protein, much was written about EPO. Although much has been learned and published, new, exciting data are becoming ava- able on almost a daily basis. Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology compiles both pertinent historical and very recent research on this molecule and its clinical utility. The book is divided into two sections: Background and Basic Science and Clinical Uses of Recombinant Erythropoietins. To begin, Israels and Israels describe the biology of red cells, the hierarchy of erythropoietic progenitor cells, their development to mature cells, and the effects of endogenous EPO on their development. Foote summarizes the historical interest in, and search for, an erythropoietic factor. Once EPO was identified, cloned, and expressed, the path was set for the study of other aspects of EPO biology both within e- thropoiesis and other cellular systems.

• Activation
• anemia
• biology
• biotechnology
• blood cell
• cancer
• cell
• cell physiology
• erythropoietin
• metabolism
• pharmacokinetics
• physiology
• regulation
• research
• signal transduction

• Amgen Inc., Thousand Oaks, USA

  Steven G. Elliott, Graham Molineux

• MA Foote Associates, Westlake Village, USA

  Mary Ann Foote

Policies and ethics